JP Morgan Chase
RYTM icon

JP Morgan Chase’s Rhythm Pharmaceuticals RYTM Stock Holding History

JP Morgan Chase’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$4.33M – 7703
2024
Q1 		$4.33M Buy
+100,000
New +$4.38M ﹤0.01% 3214

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

JP Morgan Chase's RYTM Position: Q1 2026 in Review

JP Morgan Chase increased its Rhythm Pharmaceuticals (RYTM) stake by 9.1% in Q1 2026, buying an estimated $12.6M and bringing the position to 1,553,644 shares worth $120M. The position accounts for 0.01% of the portfolio, ranked #910.

JP Morgan Chase first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $152M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • JP Morgan Chase held 1,553,644 shares of Rhythm Pharmaceuticals worth $120M as of Q1 2026.
  • JP Morgan Chase bought 129,655 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • Rhythm Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #910 holding.
  • JP Morgan Chase first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • JP Morgan Chase's Rhythm Pharmaceuticals position peaked at $152M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.